Monitoring Clostridium difficile infection in an acute hospital: prevalence or incidence studies?
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Surveillance of Clostridium difficile infection (CDI) is an essential component of a CDI preventative programme.
The aim of this study was to evaluate two methods of CDI surveillance.
Prevalence of CDI, antibiotic use and associated co-morbidity was assessed weekly on two wards over 6 weeks. In addition, CDI incidence surveillance was performed on all new CDI cases over a 13-week period. Cases were assessed for CDI risk factors, disease severity, response to treatment and outcome at 6 months.
Clostridium difficile infection prevalence was 3.5% (range 2.9–6.1%) on the medical ward and 1.1% (range 0–3.5%) on the surgical ward. Patients on the medical ward were older and more likely to be colonised with MRSA; however, recent antibiotic use was more prevalent among surgical patients. Sixty-one new CDI cases were audited. Patients were elderly (mean age 71 years) with significant co-morbidity (median age adjusted Charlson co-morbidity score 5). CDI ribotypes included 027 (29 cases) 078 (5) and 106 (4). Eight patients developed severe CDI, seven due to 027. Antibiotic use was common with 56% receiving three or more antibiotics in the preceding 8 weeks. Twenty-four patients had died at 6 months, five due to CDI.
Clostridium difficile infection prevalence gives a broad overview of CDI and points to areas that require more detailed surveillance and requires little time. However, patient-based CDI incidence surveillance provides a more useful analysis of CDI risk factors, disease and outcome for planning preventative programmes and focusing antibiotic stewardship efforts.
- Bignardi GE (1998) Risk factors for Clostridium difficile infection. J Hosp Infect 40(1):1–15 CrossRef
- Carignan A, Allard C, Pepin J, Cossette B, Nault V, Valiquette L (2008) Risk of Clostridium difficile infection after perioperative antibacterial prophylaxis before and during an outbreak of infection due to a hypervirulent strain. Clin Infect Dis 46(12):1838–1843 CrossRef
- Pepin J, Saheb N, Coulombe M-A et al (2005) Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 41(9):1254–1260 CrossRef
- Ricciardi R, Rothenberger DA, Madoff RD, Baxter NN (2007) Increasing prevalence and severity of Clostridium difficile colitis in hospitalized patients in the United States. Arch Surg 142(7):624–631 CrossRef
- Health Protection Agency Annual counts and rates of C. difficile (2007). http://www.hpa.org.uk
- Loo VG, Poirier L, Miller MA et al (2005) A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 353(23):2442–2449 CrossRef
- Pepin J, Valiquette L, Alary M-E et al (2004) Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 171(5):466–472 CrossRef
- Warny M, Pepin J, Fang A et al (2005) Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 366(9491):1079–1084 CrossRef
- Kuijper EJ, Barbut F, Brazier JS et al (2008) Update of Clostridium difficile infection due to PCR ribotype 027 in Europe. Euro Surveill 13(31):31
- Drudy D, Harnedy N, Fanning S, Hannan M, Kyne L (2007) Emergence and control of fluoroquinolone-resistant, toxin A-negative, toxin B-positive Clostridium difficile. Infect Control Hosp Epidemiol 28(8):932–940 CrossRef
- Long S, Fenelon L, Fitzgerald S et al (2007) First isolation and report of clusters of Clostridium difficile PCR 027 cases in Ireland. Euro Surveill 12(4):E070426.3
- Health Protection Surveillance Committee (2008) Surveillance, diagnosis & management of C. difficile-associated disease in Ireland. http://www.hpsc.ie (ISBN: 978-0-9551236-3-4)
- Kuijper EJ, Coignard B, Tull P et al (2006) Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infect 12(Suppl 6):2–18 CrossRef
- Flanders WD, O’Brien TR (1989) Inappropriate comparisons of incidence and prevalence in epidemiologic research. Am J Public Health 79(9):1301–1303 CrossRef
- Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373–383 CrossRef
- McNulty C, Logan M, Donald IP et al (1997) Successful control of Clostridium difficile infection in an elderly care unit through use of a restrictive antibiotic policy. J Antimicrob Chemother 40(5):707–711 CrossRef
- Climo MW, Israel DS, Wong ES, Williams D, Coudron P, Markowitz SM (1998) Hospital-wide restriction of clindamycin: effect on the incidence of Clostridium difficile-associated diarrhea and cost. Ann Intern Med 128:989–995
- Biller P, Shank B, Lind L et al (2007) Moxifloxacin therapy as a risk factor for Clostridium difficile-associated disease during an outbreak: attempts to control a new epidemic strain. Infect Control Hosp Epidemiol 28(2):198–201 CrossRef
- Sundram F, Guyot A, Carboo I, Green S, Lilaonitkul M, Scourfield A (2009) Clostridium difficile ribotypes 027 and 106: clinical outcomes and risk factors. J Hosp Infect 72(2):111–118 CrossRef
- Monitoring Clostridium difficile infection in an acute hospital: prevalence or incidence studies?
Irish Journal of Medical Science
Volume 181, Issue 3 , pp 315-320
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Clostridium difficile
- Prevalence study
- Incidence study
- Ribotype 027
- Industry Sectors
- Author Affiliations
- 1. Department of Surgery, Beaumont Hospital, Smurfit Building, Dublin 9, Ireland
- 2. Department of Microbiology, Beaumont Hospital, Dublin 9, Ireland
- 3. Health Protection Surveillance Centre, Dublin, Ireland